The desire to study new drugs at an earlier stage of the disease, especially in the presymptomatic group, has been a priority for years now. Shifting away from the gold standard endpoints and toward an evolving set of biomarkers, definitive to each stage of the disease, is a step in the right direction. However, some caution that this could raise the prospect that the FDA will approve new drugs that don’t actually do anything to alter the course of the disease.
Mostly, this is welcome news for researchers, drug developers, and will contest attorneys alike. Hopefully, these new requirements will allow researchers and drug makers to develop appropriate medications that will forestall, or even prevent, the spread of this devastating disease. Furthermore, the development of a successful drug could help prevent will contest litigation on the basis of lack of testamentary capacity. If you enjoyed reading this, check out our blog on “Improving Alzheimer’s Diagnosis” for an in-depth discussion of how the disease can impact a will contest.